Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;92(4):331-337.
doi: 10.1002/ajh.24632. Epub 2017 Feb 13.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

Sameh Gaballa  1 , Rima Saliba  1 , Betul Oran  1   2 , Jonathan E Brammer  1 , Julianne Chen  1 , Gabriela Rondon  1 , Amin M Alousi  1 , Partow Kebriaei  1   2 , David Marin  1   2 , Uday R Popat  1   2 , Borje S Andersson  1   2 , Elizabeth J Shpall  1   2 , Elias Jabbour  3 , Naval Daver  3 , Michael Andreeff  3 , Farhad Ravandi  3 , Jorge Cortes  3 , Keyur Patel  4 , Richard E Champlin  1   2 , Stefan O Ciurea  1   2
Affiliations

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

Sameh Gaballa et al. Am J Hematol. 2017 Apr.

Abstract

In patients with AML with FMS-like tyrosine kinase 3 (FLT3) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) on outcomes after transplant remains unclear. We identified 200 patients with FLT3-AML who underwent SCT at our institution. Disease status at transplant was: first or second complete remission (CR1/CR2, n = 119), high-risk CR (third or subsequent CR, marrow hypoplasia, or incomplete count recovery) (CR-HR, n = 31), and morphological evidence of active disease (AD, n = 50). The median follow-up was 27 months, and the 2-year overall and progression-free survival were 43% and 41%, respectively. Relapse was highest in the AD group (85%) and the CR-HR FLT3 MRD positive group (72%), followed by CR-HR FLT3 MRD negative (58%), CR1/CR2 FLT3 MRD positive (39%), and lowest in the CR1/CR2 FLT3 MRD negative group (23%). On multivariate analysis, independent factors influencing the risk of relapse were detectable morphological disease and FLT3 MRD by PCR pre-transplant. Factors that did not influence the relapse risk included: age, graft type, graft source, type of FLT3 mutation, or conditioning intensity. Morphologic and molecular remission status at the time of transplant were key predictors of disease relapse and survival in patients with FLT3-AML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Cumulative incidence of relapse according to disease status on morphologic analysis and FLT3 status at the time of transplant. 1B. Progression-free survival according to disease status on morphologic analysis and FLT3 status at the time of transplant
Figure 1
Figure 1
A. Cumulative incidence of relapse according to disease status on morphologic analysis and FLT3 status at the time of transplant. 1B. Progression-free survival according to disease status on morphologic analysis and FLT3 status at the time of transplant
Figure 2
Figure 2
Overall survival and progression-free survival
See this image and copyright information in PMC

Comment in

References

    1. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335. - PubMed
    1. Song Y, Magenau J, Li Y, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone marrow transplantation. 2015 - PMC - PubMed
    1. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624–631. - PubMed
    1. Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65:9643–9650. - PubMed
    1. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735–741. - PubMed

MeSH terms

Substances